Rhinophyma is a trajectory, so why does the record start at the surgeon's office?

The question at the consult that patients can't answer

A rhinophyma consult comes down to one simple question: how fast has this changed? The surgeon wants to know whether the thickening crept in over a decade or jumped in the last eighteen months. Is it still swelling, or has it settled into firm tissue? Did the pores widen first, or the shape of the nose?

And the patient often has nothing to show. A few holiday photos. A driver's license. A wedding album where the nose sits in shadow at the wrong angle.

Rhinophyma is the thickened, enlarged nose that comes from phymatous rosacea (rosacea that changes the texture and bulk of the skin). It's the most visible form the condition takes. It's also the one where the medical record tends to begin on the day someone decides to operate.

The blank timeline

We call this the blank timeline. Phymatous change gets filed as an ending, a late-stage cosmetic disfigurement to be corrected surgically, even though the dermatology literature grades it in stages. Stages can be tracked. Endings can't.

That framing gap does damage on both sides of the exam table. Patients don't document what they've been told is just what happens eventually. Researchers work from whoever turns up for surgery, so they publish case series that open with a before photo taken the week of the procedure.

So the question that would help time treatment, what the trajectory actually looks like, is exactly the one the evidence base is worst at answering.

Stages can be tracked. Endings can't.

Why 'late-stage cosmetic problem' is the wrong frame

The older classification helped build the ending story. The National Rosacea Society's 2002 standard classification (Wilkin et al., JAAD 2002) split rosacea into four subtypes, with phymatous as its own category. It was easy to read that list as a ladder: flushing first, bumps next, nose last.

The 2017 update moved away from that. The global ROSCO panel (Tan et al., British Journal of Dermatology 2017) and the NRS expert committee (Gallo et al., JAAD 2018) both switched to a phenotype approach, where a phenotype is simply an observable feature. Both named phymatous changes as enough on their own to diagnose rosacea. That puts thickening in the same group as persistent redness across the center of the face: a feature you can see and grade, not a final chapter. Despite mention of progression between subtypes, there has been no convincing evidence that patients can progress or regress along the rosacea subtype spectrum ([source](https://cdn.mdedge.com/files/s3fs-public/Wang%20rosaceaCT104001070.PDF))

But public understanding lags consensus papers by years. Search for rhinophyma and the results lean heavily toward surgery pages and before-and-after galleries. The condition still gets discussed almost entirely at the moment of removal.

What the literature actually documents

Staging criteria exist. The NRS standard grading system (Wilkin et al., JAAD 2004) grades phymatous change at three levels, running from enlarged pores with no change in shape, through contour change, to contour change with nodules. Phymatous changes graded 3 corresponds to 'phymatous rosacea' in Wilkin et al.'s standard grading system ([source](http://www.rosacea.org/physicians/grading-system-for-rosacea/view-online)) You can photograph every one of those distinctions. A phone camera held at a consistent angle would capture them all.

The treatment literature mostly doesn't. Published rhinophyma work is dominated by surgical and laser case series (electrosurgery, CO2 laser, scalpel decortication) judged on their results after the operation. Van Zuuren's Cochrane review found no studies could be included addressing treatment of phymatous rosacea (subtype 3) ([source](https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003262.pub5/full)) What those series usually lack is anything from before the consult: how quickly the tissue grew, whether it went through inflamed phases, how it responded to earlier medical treatment.

Funding has the same shape. Search NIH RePORTER for rhinophyma or phymatous rosacea and the results thin out fast next to rosacea research generally, most of what turns up is surgical technique, not the kind of longitudinal tracking that would need years of follow-up to fund. If a condition is framed as cosmetic and surgical, it doesn't attract money for long-term cohort studies. Without cohorts, nobody produces the progression data that would change the framing.

Two consults, same nose

Here's a hypothetical. A patient in their fifties has had central facial redness for years. Over a couple of years they notice the pores on their nose getting coarser and the tip looking fuller.

In version one, they walk into a surgical consult with nothing but memory. They think it started maybe five years ago. They can't say whether it's still growing. The surgeon has to make a call on timing and technique from a single snapshot: today's nose.

In version two, they bring a series. It's the same front, profile and base-of-nose views, taken every few weeks by the same window, with short notes on flares and on whatever their dermatologist had them using. The series shows a stretch where the tip swelled and settled twice, then a period of steady, firm growth. Now the conversation is different. Is there an inflammatory component worth treating medically first? Has the tissue settled enough to operate on?

Version two didn't take any special equipment. Someone just had to decide the timeline was worth recording.

What changes if the timeline matters

If phymatous change is a trajectory, then early documentation counts as clinical evidence. Dermatology reviews generally put early, more inflamed phymatous change at the stage where medical options such as oral isotretinoin come up, and established fibrous tissue at the stage for surgical or ablative (tissue-removing) treatment. In an early, actively inflamed phase, prescription treatment may help control inflammation or slow thickening in selected patients ([source](https://psdermatology.com/blog/rhinophyma-vs-rosacea-early-signs/)) A photo series can help show which side of that line a patient is on. A single photo can't.

It changes research, too. Consistent photo records kept by patients are exactly the longitudinal data (data that follows the same people over time) today's case series are missing. The funding gap and the data gap feed each other, and the cheapest place to break that loop is on the patient's side.

Skin tone matters here. Redness looks very different on darker skin, so on Fitzpatrick IV to VI skin (the darker end of the standard six-type scale) texture and contour are often more reliable things to photograph than color. It's worth logging burning, stinging or tightness as well. How skin feels, its sensory phenotype, doesn't depend on how redness shows up on camera.

Where Skinframe fits

We built Skinframe around a simple idea: a photo only counts as evidence when you can compare it with the last one. It's built for repeat photos taken the same way each time, with per-feature notes instead of one blended severity score, so thickening, pore size and redness each get their own line. Skinframe's camera view guides framing with a live oval face-placement guide that brightens when the face is well positioned, a proximity hint pill that coaches distance and single-face detection using Apple's Vision framework, and small registration corner marks styled like a clinical-photography reference. It also offers a toggleable ghost overlay of the user's most recent selfie so they can match pose and position to prior days, a one-time first-capture tip suggesting a plain dark backdrop for consistency, and locks white balance and exposure (after a brief auto-settle) plus a soft fill-light flash so day-to-day photos are lit and colored consistently for comparison. Your photos stay on your device.

We won't tell you what your nose is doing or when to have surgery. No app should. There's no rosacea-specific trial showing that tracking apps improve outcomes. Research in adjacent conditions like atopic dermatitis and psoriasis suggests patient-reported tracking helps clinic visits go better, and Skinframe applies the same approach to rosacea. The goal is modest: when you sit down with a dermatologist or surgeon, the timeline isn't blank.

Talk to your dermatologist about any change in the shape or texture of your nose, ideally long before a surgical consult.

What we're tracking next

We're looking for any prospective study, one that follows phymatous change forward in time instead of reconstructing it at surgery. We haven't been able to turn one up. If we find one, we'll write it up. If there isn't one, that absence is the story.